Skip to main
MANE

VeraDermics Inc (MANE) Stock Forecast & Price Target

VeraDermics Inc (MANE) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veradermics is poised for success as their innovative product, VDPHL01, has shown promising results and has potential to capture a large market in the aesthetic and dermatological industry. The company also has a strong pipeline of potential treatments, such as ABS-201, Breezula, and HMI-115, which are expected to receive FDA approval. While there are risks associated with competition and financing, the company's multichannel strategy and focus on a market that is not dependent on insurance coverage make it a sound investment for the future.

Bears say

Veradermics is poised for potential success in the hair loss market with its promising drug, VDPHL01, which targets both male and female patients and has potential for international approval and launch. The drug has the potential to fill a gap in the limited hair loss treatment options, making it desirable for patients. However, the company's increased expenses for development and commercialization may pose a risk for financing, and its success ultimately depends on the results of upcoming trials and interest from larger players in the pharmaceutical industry. As a result, a cautious approach is recommended when evaluating investment in Veradermics's stock.

VeraDermics Inc (MANE) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of VeraDermics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About VeraDermics Inc (MANE) Forecast

Analysts have given VeraDermics Inc (MANE) a Strong Buy based on their latest research and market trends.

According to 6 analysts, VeraDermics Inc (MANE) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

VeraDermics Inc (MANE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.